GU CANCERS SYMPOSIUM: Conference Highlights. 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY GENITOURINARY CANCERS SYMPOSIUM.
In: Urology Times, Jg. 52 (2024-03-01), Heft 3, S. 22-23
Online
serialPeriodical
Zugriff:
The article discusses highlights of the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium held in San Francisco, California. Topics included link of darolutamide to fewer hospitalizations in metastatic hormone-sensitive prostate cancer patients, cabozantinib and pembrolizumab therapy for urothelial carcinoma, and urinary minimal residual disease-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in non-muscle-invasive bladder cancer.
Titel: |
GU CANCERS SYMPOSIUM: Conference Highlights. 2024 AMERICAN SOCIETY OF CLINICAL ONCOLOGY GENITOURINARY CANCERS SYMPOSIUM.
|
---|---|
Autor/in / Beteiligte Person: | DOBKOWSKI, DARLENE ; ROSA, KRISTI ; BRODERICK, JASON M. |
Link: | |
Zeitschrift: | Urology Times, Jg. 52 (2024-03-01), Heft 3, S. 22-23 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 0093-9722 (print) |
Schlagwort: |
|
Sonstiges: |
|